Financials data is unavailable for this security.
Inc stmt in EURIncome statement in EUR
Year on year
Bayer AG had relatively flat revenues (34.94bn to 35.02bn), though the company grew net income 61.91% from 4.53bn to 7.34bn. A reduction in the cost of goods sold as a percentage of sales from 33.64% to 32.51% was a component in the net income growth despite flat revenues.
|Net profit margin||10.12%|
|Return on assets||4.35%|
|Return on equity||10.22%|
|Return on investment||5.56%|
Cash flow in EUR
Bayer AG increased its cash reserves by 299.21%, or 5.68bn. The company earned 8.13bn from its operations for a Cash Flow Margin of 23.23%. In addition the company used 432.00m on investing activities and also paid 1.88bn in financing cash flows.
|Cash flow per share||7.01|
|Price/Cash flow per share||14.02|
|Book value per share||45.61|
|Tangible book value per share||15.07|
Balance sheet in EUR
|Total debt/total equity||0.3662|
|Total debt/total capital||0.2677|
Growth rates in EUR
Year on year, growth in dividends per share increased 3.70% while earnings per share excluding extraordinary items fell by -17.14%. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth ranked highest relative to its industry peers, while earnings per share growth is in-line with the industry average.
|Div yield(5 year avg)||1.89%|
|Div growth rate (5 year)||8.06%|
|Payout ratio (TTM)||62.98%|
|EPS growth(5 years)||5.09|
|EPS (TTM) vs |
TTM 1 year ago